Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Status:
Completed
Trial end date:
2017-11-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand why people with indigestion have gastrointestinal
symptoms and in particular to understand whether symptoms are related to increased
sensitivity to nutrients in the small intestine and to a hormone (GLP1) which is normally
released from the small intestine in response to nutrients. We propose to study the
contribution of GLP1 to intestinal sensitivity with a drug (exendin 9-39) that blocks the
effects of GLP1.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)